Analysis of Proteolytic Processes and Enzymatic Activities in the Generation of Huntingtin N-Terminal Fragments in an HEK293 Cell Model

Andrew T. N. Tebbenkamp1,2, Keith W. Crosby1,2, Zoe B. Siemienski1,2, Hilda H. Brown1,2, Todd E. Golde1, David R. Borchelt1,2*

1 Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, McKnight Brain Institute, University of Florida, Gainesville, Florida, United States of America, 2 SantaFe HealthCare Alzheimer’s Disease Research Center, University of Florida, Gainesville, Florida, United States of America

Abstract

Background: N-terminal fragments of mutant huntingtin (htt) that terminate between residues 90–115, termed cleavage product A or 1 (cp-A/1), form intracellular and intranuclear inclusion bodies in the brains of patients with Huntington’s disease (HD). These fragments appear to be proteolytic products of the full-length protein. Here, we use an HEK293 cell culture model to investigate huntingtin proteolytic processing; previous studies of these cells have demonstrated cleavage of htt to cp-A/1 like htt fragments.

Results: Recombinant N-terminal htt fragments, terminating at residue 171 (also referred to as cp-B/2 like), were efficiently cleaved to produce cp-A/1 whereas fragments representing endogenous caspase, calpain, and metalloprotease cleavage products, terminating between residues 400–600, were inefficiently cleaved. Using cysteine-labeling techniques and antibody binding mapping, we localized the C-terminus of the cp-A/1 fragments produced by HEK293 cells to sequences minimally limited by cysteine 105 and an antibody epitope composed of residues 115–124. A combination of genetic and pharmacologic approaches to inhibit potential proteases, including γ-secretase and calpain, proved ineffective in preventing production of cp-A/1.

Conclusions: Our findings indicate that HEK293 cells express a protease that is capable of efficiently cleaving cp-B/2 like fragments of htt with normal or expanded glutamine repeats. For reasons that remain unclear, this protease cleaves longer htt fragments, with normal or expanded glutamine expansions, much less efficiently. The protease in HEK293 cells that is capable of generating a cp-A/1 like htt fragment may be a novel protease with a high preference for a cp-B/2-like htt fragment as substrate.

Introduction

Huntington’s disease (HD) is an autosomal-dominant, progressive, and fatal neurodegenerative disease that is caused by an expansion of a CAG trinucleotide repeat in the first exon of the htt gene (GenBank:NM_002111) [1]. Disease invariably occurs when the CAG repeat in the first exon, which codes for glutamine (Q), expands to ≥39 consecutive CAG repeats. Patients carrying the polyQ expansion exhibit general brain atrophy, prominent cortico- and striatal-neuron loss, and harbor inclusion bodies composed of mutant htt throughout their central nervous system [2–4]. These inclusion bodies are found in the nucleus and cytoplasm, and react to antibodies recognizing N-terminal epitopes of htt [5,6]. Lukens and co-workers identified two N-terminal htt cleavage products in HD brains and in cell culture models that were termed cleavage product-A (cp-A, C-terminus mapped to amino acids 104–114 in cell models) and cleavage product-B (cp-B, C-terminus mapped to amino acids 146–214) [7]. The antibody binding characteristics of the pathologic inclusion bodies in HD brain are consistent with cp-A/1 sized fragments in that nuclear inclusions, and most cytoplasmic inclusions, are composed of a htt cleavage product whose C-terminus lies between antibody epitopes composed of residues 85–90 and 115–124 [7,8]. These antibody binding characteristics are shared by inclusions throughout the CNS, and thus it appears that the protease responsible for generating cp-A/1 is expressed broadly in CNS neurons. More recently, a report by Landles et al. provided evidence that the smallest N-terminal fragment that is produced in the brains of HdhQ150 knock-in mice (the presumed cp-A equivalent) may be generated by cleavage at residue 90 [9]. Thus, although there is agreement regarding the approximate length of the pathologic mutant htt fragment, the precise length of this fragment remains unclear.

* E-mail: borchelt@mbH.ufl.edu

Citation: Tebbenkamp ATN, Crosby KW, Siemienski ZB, Brown HH, Golde TE, et al. (2012) Analysis of Proteolytic Processes and Enzymatic Activities in the Generation of Huntingtin N-Terminal Fragments in an HEK293 Cell Model. PLoS ONE 7(12): e50750. doi:10.1371/journal.pone.0050750

Editor: Xiao-Jiang Li, Emory University, United States of America

Received August 6, 2012; Accepted October 24, 2012; Published December 7, 2012

Copyright: © 2012 Tebbenkamp et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Coalition for a Cure; Huntington’s Disease Society of America, and the SantaFe HealthCare Alzheimer’s Disease Research Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: borchelt@mbi.ufl.edu
Many studies suggest that shorter htt fragments are more toxic than the full-length protein. Cells transfected with vectors expressing N-terminal fragments of mutant htt show more aggregates and are more susceptible to apoptotic stimuli than cells transfected with full-length mutant htt [10,11]. Similarly, transgenic mice that express mutant N-terminal htt fragments exhibit more robust phenotypes than their counterparts expressing full-length mutant htt. For example, the R6/2 mice and N171-82Q mice, which express the first exon of htt and the first 171 amino acids (into the fourth exon), respectively, exhibit robust HD-like inclusion pathology and die at three months and six months, respectively [12,13]. In contrast, the YAC128 and BACHD mice express full-length htt (67 exons) but are slower to develop HD-like inclusion pathology and live much longer [14,15]. Similarly, mice with an expanded polyQ knock into their endogenous htt allele are also slower to exhibit HD-like inclusion pathology and live normal life spans [for review see [16]]. A comparison between knock-in mice (HdhQ150) and R6/2 mice showed that the progressive behavioral impairments and aggregate deposition of the HdhQ150 mice were similar to those of the R6/2 mice, but of a slower and delayed progression [17].

The precise location of the C-terminus of cp-A-sized htt fragments is unknown but, as described above, it is thought to be within a region bounded by residues 90 and 115. Several laboratories have developed cell culture models that recapitulate proteolytic processing of htt and most information regarding the C-terminus of cp-A sized fragments has come from studies of these models. Lukes and co-workers developed a model in rodent NG108 cells in which expression of an htt construct that included the first 502 residues of htt was cleaved to produce cp-A as well as cp-B [7]. Further, the authors showed that mutating C109 and E110 to alanines, and mutating N111 and H112 to alanines within an N502 htt construct led to decreased production of cp-A sized fragments. Another report by Kim et al. produced evidence that also suggested the C-terminus of cp-A lies between 104 and 114 [18]. In previous work in an HEK293 cell model in which a cp-B sized htt fragment was expressed (N171), we also narrowed the C-terminus of cp-A to between residues 90 and 115 [8]. However, in a PC12 cell model in which full-length htt was expressed, Ratovitski and colleagues found no effect on cp-A generation when they deleted amino acids 105–114 of their htt construct and concluded that the PC12 cell model generated novel htt cleavage products and termed the smallest N-terminal fragment cp-1 [19]. In the PC12 cell model, Ratovitski and colleagues also observed a cp-B sized fragment, which they termed cp-2 and further demonstrated that it encompasses residues 1 to 167 [20]. Apart from cp-A/1 and cp-B/2, there are six well-defined htt cleavage products, generated by calpains at residues 469 and 536, caspases at residues 513, 552, and 586, or matrix metalloproteinase-10 (MMP-10) at residue 402 [21–24].

In this current report, we have further evaluated whether HEK293 cells are useful models to examine htt proteolytic cleavage. We utilized bioinformatic and gene expression analysis, pharmacological inhibition, and various htt substrates to further characterize this model. Our data suggest that a novel proteolytic activity is expressed by these cells that can cleave htt to produce a cp-A/1 like fragment. This fragment possesses a C-terminus of that is minimally limited by residues 105–115.

**Methods**

**Reagents**

Cell culture media used was DMEM/High glucose (HyClone) supplemented with 10% horse serum and 2 mM L-glutamine. For transfections, DNA and Lipofectamine were diluted in Opti-MEM following the manufacturer’s protocol (Invitrogen, Carlsbad, CA). Antibodies used were: htt1-17, a generous gift from Dr. Ricky Hirschhorn (Hood College); 1H6, 2B4, and EM48 were purchased from Millipore (Boston, MA); htt81-90 was previously described [10]; htt3-16 and htt64-82 were purchased from Sigma-Aldrich (St. Louis, MO); LC3 was a generous gift from Dr. William Dunj Jr. (University of Florida) [25]; anti-activated calpain-1 was a generous gift from Dr. Kevin Wang (University of Florida, Department of Psychiatry, Gainesville, FL) [26]; anti-mouse and anti-rabbit antibodies conjugated to HRP were purchased from Kirkegaard & Perry Laboratories (Gaithersburg, MD).

**Generation of plasmids**

To make N386-18Q, we used cDNA encoding htt amino acids 171–586 generated by GenScript (Piscataway, NJ). This cDNA was excised from its vector using XhoI and SalI then ligated into the vector pcDNA3.1(+) encoding htt N171-18Q [8]. Other htt lengths were generated by standard PCR techniques using the htt 171–586 cDNA as a template and primers shown in Table S1. All htt vectors were sequenced to verify the number of glutamines and coding sequence at the University of Florida Interdisciplinary Center for Biotechnology Research.

**Cell transfections and immunoblots**

Human embryonic kidney 293 (HEK293) cells were plated in 60 mm poly-D-lysine-coated dishes 24 hours before transfection. Once cells were 80% confluent, they were transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) using the manufacturer’s protocol. Media was exchanged 24 hours post-transfection and cells were harvested at 48 hours post-transfection. In relevant experiments, pharmacological inhibitors were added at the 24-hour time point with the media exchange. The inhibitors used are as follows (targets in parentheses): Ucf-101 (HtrA2/Omi); AEB531 at 0.1 mM (serine proteases); PMSF at 1.0 mM (serine proteases); Leupeptin at 20 μM (trypsin-like and cysteine proteases); Pepstatin A at 0.1 μM (and 100 μM (aspartyl proteases); E-6 at 50 μM (cysteine proteases); EDTA at 5 mM (metal chelator/metallopeptidases); EGTA at 5 mM (calcium chelator); Bestatin Methyl Ester at 100 μM (aminopeptidases); MG-132 at 10 μM (proteasome); Chloroquine at 100 μM (lysosome neutralizer); 3-methyladenine at 10 mM (apoptagony inhibitor); Rapamycin at 0.2 mM (mTOR, autophagy activator); MDL28170 at 30 μM (calpain-1 and calpain-2); DAPT N-[3,5-difluorophenacyl]-L-alanyl-S-phenylglycine t-butyl ester] at 20 μM (γ-secretase); LY411,575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide] at 1 μM (γ-secretase). Chemicals were purchased from Calbiochem (San Diego, CA) or Sigma-Aldrich (St. Louis, MO), except for DAPT and LY411,575, which were purchased from Cayman Chemical Co (Ann Arbor, MI) or were kindly provided by Abdul Fauq (Mayo Clinic Jacksonville, Jacksonville, FL) [27], respectively. Pharmacological inhibitors were resuspended in their appropriate diluent, aliquoted, and frozen at −80°C until use within approximately 1–2 weeks of purchase for all experiments.

Cells were collected and lysed in PBS with protease inhibitor cocktail (Sigma, P8340) by brief sonication with a probe sonicator (Micronson XL2000, 2 watts at 22.5 kHz; Misonix, Farmingdale, NY), followed by a brief centrifugation at 3000×g to pellet membranous material. The protein concentration of cell lysate supernatant was determined with a colorimetric BCA assay (Pierce, Rockford, IL). Equal amounts of protein were boiled in Laemmli buffer [28] then resolved by SDS-PAGE through 4–20%
Results

Substrate specificity of the cp-A/1 generating protease(s) in HEK293 cells

The model system we used in this study is based on expression of htt N171-18Q fragments in HEK293 cells, in which we observe the production of a cleavage product of cp-A/1 size (Fig. 1). HEK293 cells are derived from human embryonic kidney and are fibroblastic in appearance, but transcriptional profiling of these cells has demonstrated that their expression profile overlaps with neural cell types [29]. Notably, a cell line derived from mouse lung fibroblasts (LTK(-)) does not show cleavage of htt N171-18Q to a cp-A/1 sized fragment (Fig. 1).

The N171-18Q cleavage product produced in HEK293 cells binds antibodies N-terminal to amino acid 115 but lacks reactivity to the 1H6 antibody, which recognizes amino acids 115–124 (Fig. 2A) [8]. To avoid issues regarding the aggregation of huntingtin fragments with expanded polyglutamine repeats, we primarily used htt constructs with normal repeat lengths. In our hands, in these cells, htt N171 substrates with normal repeat lengths were cleaved as efficiently as N171 substrates with expanded repeats (Fig. 2B). Longer substrates such as htt N586 (fragments encompassing the first 586 amino acids of htt that would be generated by caspase 6 cleavage [21,22]) were cleaved inefficiently whether the repeat length is short (18Q) or expanded (82Q) (Fig. 2B; the arrows on panel B mark the expected positions of cp-A and cp-B like fragments derived from N586 constructs).

To determine whether other htt N-terminal fragments generated by calpain, caspase, or MMP-10 are more efficient substrates for subsequent cleavage, we transfected htt cDNAs encoding 18Q versions of these htt fragments into HEK293 cells and then assessed the generation of cp-A/1 and cp-B/2 by immunoblot (Fig. S1). Htt fragments that would be generated by calpain, caspase, and MMP-10 endoproteolysis (N402, N469, N513, N536, N532, and N586) were capable of generating only small amounts of fragments that migrated at the sizes expected for cp-A/1 and cp-B/2. These data establish that N-terminal htt fragments of a size similar to natural cp-B/2 are a preferred substrate of the protease in HEK293 cells that is capable of generating a cp-A/1-like fragment.

To gain insight into the site of cleavage to generate cp-A/1, we asked whether the cp-A/1-sized fragment that is generated by proteolysis of N171-18Q (cp-B/2-like) could be covalently modified by biotinylation reagents that specifically react with cysteine residues (Fig. 3A). The N171-18Q cDNA possesses 4 cysteine residues located at 105, 109, 137, and 152. If proteolysis occurs C-terminal to residue 105 or 109, then cysteines 105 and/
or 109 would be present for reactivity, allowing for detection of immunoprecipitated cp-A/1 by streptavidin conjugated to horse-radish peroxidase (HRP) (Fig. 3A). In cells that had been transfected with htt N171-18Q, lysed, reacted with EZ-link Biotin BMCC, and then immunoprecipitated with htt64-82 antibody, we observed a protein band of similar size to cp-A/1 on immunoblots after detection with streptavidin HRP (Fig. 3B). This band was not found in untransfected cells, or when cell lysates were not reacted with the cysteine biotinylation reagent. In parallel, we performed an immunoblot of the htt64-82 immunoprecipitates with htt3-16 antibodies confirming efficient immunoprecipitation of htt N171-18Q and htt cp-A/1 (Fig. 3C). For reasons that remain unclear, detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP (Fig. 3C). For reasons that remain unclear, detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently immunoprecipitated (last lane of 2B and 2C). To confirm we could biotinylate detection of uncleaved N171-18Q (cp-B/2) with streptavidin–HRP was very poor despite indications it was efficiently im
observe a decrease in htt N171-18Q cleavage that was proportional to the decrease in activated capn1 levels in the HEK293 cells stably expressing shRNAi to capn1.

We continued to analyze htt residues for known substrate sequences as a means to identify the protease involved in generating cp-A/1. To do this analysis, we utilized the online peptidase database, MEROPS (http://merops.sanger.ac.uk/; [30]). We queried its search option for proteases by assessing possible cleavage events between two htt residues at a time, moving from the N- to C-terminus of residues 85 through 115. For example, we input htt P86 and L87 as P1 and P19, respectively, and proceeded sequentially to the C-terminus of htt ending with Q115. We then tabulated the number of human proteases listed (Table S3). All peptide bonds except one (C109-E110) were a substrate for at least one human protease. To narrow the list of candidates, we focused on proteases that cleave near presumptive cleavage sites at I108-I112, as suggested by Lunkes et al. [7] (Table S4). The majority of proteases that can cleave in these regions are metallopeptidases, but we also observed representatives from cysteine, serine, and aspartyl protease families.

We next attempted to gain further information on the nature of the protease involved by incubating the transfected cells with a panel of well characterized protease inhibitors. The paradigm used involved transient transfection of the cells followed by 24 hour incubation, exchanging medium with medium containing the inhibitor, and an additional 24 hour incubation before harvest. In this HEK293 cell model of transient transfection with N171-18Q vectors, we do not observe any accumulation of cp-A/1 at 24 hours; only after 48 hours post-transfection do we detect the accumulation of a cp-A/1 fragment (not shown). Unfortunately, we were unable to identify any protease inhibitors that blocked cleavage of N171-18Q to cp-A/1 (Fig. S4). Previous studies using a panel of broad-spectrum protease inhibitors have found that the aspartyl protease inhibitor, Pepstatin A, can block generation of cp-A/1 [7,18]. To investigate further, we repeated the experiment with a higher concentration (100 μM) of Pepstatin A, finding the same outcome of no change in cp-A/1 production (Fig. S4B). Thus, unfortunately, we were unable to narrow the candidate list generated by MEROPS database through the use of inhibitors.

We next examined whether the autophagy/lysosomal degradation pathways played a role in generating cp-A/1. Autophagy can coordinate with proteasomal degradation, and activation of autophagy has been shown to be protective in models of HD by enhancing removal of pathologic aggregates [reviewed in [34]]. To examine the role of autophagy in generating cp-A/1, transfected cells were treated with an inhibitor (3-methyladenine) or an activator (rapamycin) of autophagy, or chloroquine, which increases lysosomal pH and inhibits autophagic flux while still permitting autophagosome sequestration. Treating N171-18Q-transfected cells with these molecules did not block the generation

---

**Figure 3. Htt cleavage occurs C-terminal to cysteine 105.** A, The sequence of htt is shown through residue 171, the substrate used in these experiments. The first cysteine in htt is at residue 105 (bold) and represents the most N-terminal cysteine that could be labeled with sulfhydrylated biotin (Biotin-SH). This cysteine must be present for any labeling to occur. Subsequent immunoprecipitation (IP) followed by detection with streptavidin or htt antibodies was used to visualize the biotinylation. B, Detection using streptavidin-HRP of transfected cell lysate (Tfx N171-18Q, +) reacted with biotinylation reagent (Biotin, +) shows cp-B/2 and cp-A/1-sized products (arrows). Asterisks (*) signify possible multimers of htt. C, Detection of htt with the antibody htt3-16 confirms the identities of cp-B/2 and cp-A/1 (bottom two arrows). IgG from the immunoprecipitation is observed in all lanes (top arrow). The images shown are representative of at least 3 repetitions of the experiment. doi:10.1371/journal.pone.0050750.g003

**Figure 4. Knock-down of calpain-1 does not block htt cleavage.** HEK293 cells which stably express a shRNA against calpain-1 (shRNAi +) do not block cleavage of htt following transfection with cDNA encoding N171-18Q (Tfx +). Knock-down of capn1 was confirmed by immunoblot with an antibody to activated calpain-1. Htt cp-A/1 was detected with the htt81-90 (1:3000) antibody. The images shown are representative of at least 3 repetitions of the experiment. doi:10.1371/journal.pone.0050750.g004
of cp-A/1; 3-methyladenine (3-MA) caused an obvious increase in the accumulation of N171-18Q and cp-A/1 (Fig. 5). The effectiveness of these pharmacological agents was assessed by immunoblotting for microtubule associated protein light chain 3-I (LC3-1). Upon activation of autophagy, LC3-1 is modified by covalent attachment of phosphatidylethanolamine to generate a faster migrating LC3-II [for review see [35]] (Fig. 5). A small, but reproducible increase in LC3-II levels was observed in cells treated with rapamycin as expected [35] (Fig. 5). Similar to what has been reported for retinal pigment epithelial cells treated with chloroquine [36], the levels of LC3-II were increased in HEK293 cells treated with this lysosomal inhibitor (Fig. 5). Counter to what would be predicted [35], the levels of LC3-II in HEK293 cells treated with 3-MA were elevated and thus, we could not confirm that 3-MA had indeed inhibited autophagy in the transfected cells.

One protease identified in our MEROPS analyses that had multiple potential cleavage sites within htt residues 86-115 was a caspase protease capable of generating cp-A/1. Our studies indicate that, in these cells, htt fragments produced by calpain, caspase, or MMP-10 cleavage are rather weak substrates for the production of cp-A/1 and cp-B/2; whereas fragments of cp-B/2 size are a preferred substrate. Using cysteine labeling reagents, we demonstrate that we can detect a cp-A/1 fragment produced in HEK293 cells that possess at least one cysteine of which the only candidates are located at position 105 and 109. This result places the cleavage site very close to what has previously been reported by Lunkes et al. [7] and Kim et al. [18]. Using shRNAi technology, we show that lowering the levels of activated calpain does not produce a proportional reduction in the generation of cp-A/1. We also find no evidence to support the idea that γ-secretase directly generates cp-A/1 from cp-B/2 sized fragments. Unfortunately, we were unable to identify a protease inhibitor that showed an appreciable efficacy in reducing the conversion of cp-B/2 sized fragments to cp-A/1 sized fragments. The most robust effect observed was a dramatic increase in the levels of cp-B/2 and cp-A/1 in cells treated with 3-methyladenine. Collectively, our results are consistent with the hypothesis that HEK293 cells express a novel caspase-2/3 site at 513 and 552 [22], and a caspase-6 site at 586 [47]. It was unclear whether these fragments, cp-B/2 and longer, can be cleaved to cp-A/1. In a recent study of transgenic mice that express htt cDNA engineered to mimic the caspase 6 fragment [47], it was shown that inhibitors of the enzyme complex termed DAPT and LY411,575, that have been shown to have good specificity for inhibiting -secretase directly generates products appear to be similar to fragments that have been described elsewhere: cp-A/1 and cp-B/2 [7,20], an MMP-10 site at 402 [24], two calpain sites at residues 469 and 536 [23], two caspase-2/3 sites at 513 and 552 [22], and a caspase-6 site at 586 [47]. It was unclear whether these fragments, cp-B/2 and longer, can be cleaved to cp-A/1. In a recent study of transgenic mice that express htt cDNA engineered to mimic the caspase 6 fragment (N386), we demonstrated both N386-82Q and N386-18Q can be cleaved in vivo to produce cp-A/1 sized fragments [48]. Thus, it is clear that full-length htt can be processed to shorter htt fragments and that at least some htt N-terminal fragments can be further cleaved to produce cp-A/1 sized fragments.

**Discussion**

This study utilized a previously reported cell culture model of htt proteolysis to further characterize the generation of the predominant htt fragment in human HD pathology termed cp-A/1. The HEK 293 cell model could be a useful platform to identify proteases capable of generating cp-A/1. Our results indicate that, in these cells, htt fragments produced by calpain, caspase, or MMP-10 cleavage are rather weak substrates for the production of cp-A/1 and cp-B/2; whereas fragments of cp-B/2 size are a preferred substrate. Using cysteine labeling reagents, we demonstrate that we can detect a cp-A/1 fragment produced in HEK293 cells that possess at least one cysteine of which the only candidates are located at position 105 and 109. This result places the cleavage site very close to what has previously been reported by Lunkes et al. [7] and Kim et al. [18]. Using shRNAi technology, we show that lowering the levels of activated calpain does not produce a proportional reduction in the generation of cp-A/1. We also find no evidence to support the idea that γ-secretase directly generates cp-A/1 from cp-B/2 sized fragments. Unfortunately, we were unable to identify a protease inhibitor that showed an appreciable efficacy in reducing the conversion of cp-B/2 sized fragments to cp-A/1 sized fragments. The most robust effect observed was a dramatic increase in the levels of cp-B/2 and cp-A/1 in cells treated with 3-methyladenine. Collectively, our results are consistent with the hypothesis that HEK293 cells express a novel protease that cleaves htt between amino acids 105 and 114 to produce an htt fragment that possesses antibody-binding properties that are identical to the primary pathologic fragment that produces inclusions in HD brain [8].

**Substrates for the generation of cp-A/1**

A recent study identified fourteen htt cleavage products in the brains of HdhQ150 knock-in mice [9]. Eight of these cleavage products appear to be similar to fragments that have been described elsewhere: cp-A/1 and cp-B/2 [7,20], an MMP-10 site at 402 [24], two calpain sites at residues 469 and 536 [23], two caspase-2/3 sites at 513 and 552 [22], and a caspase-6 site at 586 [47]. It was unclear whether these fragments, cp-B/2 and longer, can be cleaved to cp-A/1. In a recent study of transgenic mice that express htt cDNA engineered to mimic the caspase 6 fragment (N386), we demonstrated both N386-82Q and N386-18Q can be cleaved in vivo to produce cp-A/1 sized fragments [48]. Thus, it is clear that full-length htt can be processed to shorter htt fragments and that at least some htt N-terminal fragments can be further cleaved to produce cp-A/1 sized fragments.

**Figure 5. Autophagy activators or inhibitors do not block htt proteolysis.** Top: inhibitors (3-methyladenine, 3-MA and Chloroquine, Chiq) or activators (Rapamycin, Rapa) of autophagy failed to block htt proteolysis, as detected by immunoblot with 2B4 antibody (1:1000). Treatment with 3-MA caused an increase in cp-B/2 and cp-A/1. Bottom: Detection of LC3-1 and LC3-II. LC3 antibody was used at 1:10000. The images shown are representative of at least 3 repetitions of the experiment. doi:10.1371/journal.pone.0050750.g005
In the HEK293 cell model, we find that cp-B/2 sized fragments seem to be very efficiently cleaved to produce cp-A/1 sized fragments whereas N-terminal fragments corresponding to natural products of calpain, caspase, and metalloproteinases were rather inefficiently cleaved. It is notable that we were unable to detect endogenous cp-B/2 or cp-A/1 fragments in these HEK293 cells (Fig. S7), which express endogenous human htt, suggesting that either some intermediate exists between full-length htt and cp-B/2 and cp-A/1, or that these cleavage products are produced at such a low level that they are not detectable unless precursor substrates are over-expressed. It is also noteworthy that we observed rather limited accumulation of cp-B/2 sized fragments in HEK293 cells expressing htt N386 fragments. It is possible that htt must first be cleaved to cp-B/2 and that HEK293 cells do not express high levels of the protease responsible for generating cp-B/2 or the expressed protease is not activated. It is also possible that htt fragments that are longer than any we tested are better substrates to generate cp-B/2 and that there is a preferred intermediate fragment that we have yet to identify. Overall, our data indicate that the protease in HEK293 cells that is capable of producing a cp-A/1 sized fragment prefers a cp-B/2 sized htt substrate.

**Proteolytic inhibitors in HEK293 cells**

The precise identity of the protease(s) responsible for the generation of cp-A/1-like fragments in these HEK293 cells, or any other system, remains unknown. In each attempt to identify an inhibitor of cp-A/1 production we were unsuccessful. HEK293 cells that stably express shRNAi for calpain 1 showed much lower levels of activated calpain 1, which was induced by transfection, than control cells. Thus, it seems unlikely that calpain-1 is responsible for generating cp-A/1 in our HEK293 cell model. Additionally, we found that the calpain inhibitor MDL28170, which inhibits both capn1 and capn2, failed to block the generation of cp-A/1. Finally, expression analyses indicated that capn1 and capn2 mRNA were expressed in the mouse LTK- cells that show no production of cp-A/1 (see Data File S2). Together, these data indicate that calpain cleavage is unlikely to be involved in generating cp-A/1 in the HEK 293 cells.

In an effort to narrow the focus in the search for cp-A/1 generating proteases, we tested a panel of chemical inhibitors. Unfortunately, none of the inhibitors were efficacious in reducing the generation of cp-A/1, but some of the outcomes were more definitive than others. First, we have high confidence that γ-secretase inhibitors DAPT and Ly411,575 do not lower the generation of cp-A/1. For these inhibitors, we were able to demonstrate efficacy by showing an accumulation of APP C-terminal fragments, which occurs when γ-secretase is inactive [43]. We also have high confidence that the proteasome and lysosomal proteases are not involved as we observed obvious evidence that these compounds were active within the cell. The evidence included enhanced accumulation of cp-B/2 and cp-A/1 in the case of the proteasome inhibitor MG132, and enhanced accumulation of LC3-II in cells treated with chloroquine. This latter effect has been previously reported in retinal epithelial cells [36]. Thus, we have high confidence in concluding that the proteasome or lysosomal systems are not directly involved in generating cp-A/1. However, these systems are involved indirectly because they appear to govern the stability of cp-B/2 substrate.

For the remaining panel of inhibitors, we have little corroborating evidence that the inhibitor entered cells and engaged the target proteases. It is difficult to produce positive controls for each of these inhibitors and thus the absence of efficacy produces a negative outcome that is limited in interpretation. One interpretation is that the protease responsible for generating cp-A/1 acts via a novel mechanism and is uniquely resistant to these inhibitors. Another interpretation is that for some reason the HEK293 cells were impermeable to the inhibitor that would target cp-A/1 generating protease. We were particularly surprised by the inability of Pepstatin A to inhibit the generation of cp-A/1 because previous studies have shown efficacy with this inhibitor [7,18]. Whether our findings are due to differences in the cell types used (NG108 and X57 cell lines versus HEK293 cells) is yet to be resolved. Thus, we essentially reach an impasse in which the
inhibitor studies in the HEK293 cells were uninformative regarding the identity of the protease.

**Autophagy inhibitors and htt fragment stability**

One of the most striking effects we observed was the dramatic accumulation of both the precursor htt N171-18Q and cp-A/1 cleavage product in cells treated with 3-methyladenine. This compound is described as a potent inhibitor of autophagy [35] and thus we attribute the accumulation of these htt fragments in the presence of 3-methyladenine to a blockade of autophagy. However, as noted in Figure 5, cells treated with this compound did not show the expected accumulation of LC3-I and thus we cannot reliably conclude that the accumulation of htt fragments in the presence of this compound is due to an inhibition of autophagy. 3-methyladenine has been shown to inhibit other cellular processes [for review see [35]] and it is possible that the accumulation of htt fragments is due to an effect of the compound on a process other than autophagy. However, we did observe that rapamycin treatment induced the expected modification of LC3 that is associated with activation of autophagy and yet we observed no increase in cp-A/1 production. This observation suggests that autophagy is probably not involved in generating cp-A/1 in the HEK 293 cells.

**Conclusions**

In summary, we have determined that cp-B/2-like htt fragments are efficiently cleaved substrate to produce cp-A/1 in HEK293 cells. We also provide evidence that in this cell model, cp-A/1 is generated by a cleavage event C-terminal to the cysteine residue at 105; a site similar to that identified by Lunkes et al. [7]. Lacking precise information, we cannot rule out the possibility that there are multiple C-termini for cp-A/1.

Although it is possible the protease in human HEK293 cells that cleaves cp-B/2 to cp-A/1 is not the same protease that is responsible for generating the cp-A/1 sized pathologic fragment in human HD brains, the antibody binding characteristics of the cp-A/1 fragment found in HEK293 cells is very similar to that of the pathologic fragment in inclusions [7,8]. From a combination of genetic and pharmacological inhibition of calpain-1, HtrA2, and γ-secretase, we are fairly confident that cleavage of cp-B/2 to cp-A/1 in the HEK293 cell model does not involve these proteases. Notably LY411,575 has also been reported to inhibit signal peptide peptidase [49], and thus this protease is also unlikely to be involved. We are similarly confident that cleavage of cp-B/2 to cp-A/1 does not involve the proteasome or lyosomal proteases. Our data are consistent with the notion that human cells produce a novel protease that cleaves cp-B/2 sized fragments of htt to create pathologically relevant cp-A/1 sized fragments.

**Supporting Information**

**Table S1** The sequences of sense (S) and antisense primers (AS) that were used to generate some of the htt cDNAs described in this study.

**Table S2** List of protease genes in which mRNA expression was specifically detected in the HEK293 cells as compared to the mouse L cells.

**Table S3** The number different human proteases that could cleave htt between residues 86–115 is shown. The left column shows the amino acid position of htt (based on 23Q: GenBank NM_002111). The second column shows the substrate sequence for htt amino acids that are at the designated amino acid positions. The last column shows how many human proteases are reported to cleave the bond shown in the second row. Residues 98–99 are not shown because that sequence is K-K, which is the same as residues 91–92. No human proteases were found that could cleave between htt amino acid sequences 109–110.

**Figure S1** Recombinant N-terminal fragments of htt corresponding to natural cleavage products of calpain, caspase, and MMP-10 are inefficiently cleaved to cp-A/1 and cp-B/2. Vectors engineered to express N-terminal htt fragments (18Q) were transfected into HEK293s, treated with 3-MA after 24 hours (to stabilize cleavage products – see Figure 5 of main text), and then after another 24 hours cell lysates were analyzed by immunoblot (NTf, non-transfected cells). A, This membrane was incubated with EM48 at 1:500, and shows the relative amounts of cp-A/1 from each substrate. B, The same cell lysates were analyzed separately using the antibody HttB at 1:2000 to confirm cleavage fragment identity. The images shown are representative of at least 3 repetitions of the experiment. The positions of the bands that appear to be cp-A/1 and cp-B/2 are marked by arrows. The arrowhead marks the position of a band that migrates to a position expected for a dimer, which is present to variable levels in transiently transfected cells.

**Figure S2** Full-length, purified N171-18Q can be biotinylated. Recombinant N171-18Q was incubated in the presence (+) or absence (−) of cell lysate and/or biotinylation reagent, followed by immunoprecipitation (IP) with the antibody htt64-82. Separate membranes were then incubated with HRP-conjugated streptavidin (A) or htt3-16 (B) antibodies to confirm the presence of htt. N171-18Q (bottom arrow, cp-B/2) was seen to homodimerize (+) and this dimer was of similar size to IgG used in the IP (upper arrow, IgG). The images shown are representative of at least 2 repetitions of the experiment.

**Figure S3** Htt residues 85–95 have homology to calpain-1 substrates. The positions of a putative substrate are shown at the top row, followed by an alignment of the preferred substrate for calpain-1 (capn1) and the htt sequence. Htt residues in bold are top matches to the preferred capn1 substrate at that position, capital letters rank in the top three, and lower case are outside of the top three.

**Figure S4** Broad-spectrum protease inhibitors fail to block htt cleavage. A, Representative immunoblots of HEK293 cells transfected with htt and treated with various protease inhibitors (see Methods for concentrations) for 24 hours show that no class of inhibitors was able to block proteolysis. 0.1% DMSO served as a control. EM48 was used at 1:500 to detect htt. B, A higher concentration of Pepstatin A, 100 μM, was used to compare to previous studies; 1% DMSO served as a control. NT is
cells not treated with any molecule or diluents. The antibody used was htt1-17 (1:6000). The images shown are representative of at least 3 repetitions of the experiment. (TIF)

Figure S5 An HtrA2/Omi inhibitor does not block htt cleavage. Ht1-transfected cells were either non-treated (NT) or treated with the HtrA2 inhibitor Ucf-101, followed by lysis and analysis by immunoblot. DMSO at 0.1% was a control. No detectable decrease in cleavage was observed over a range of inhibitor concentrations, as observed with the EM48 antibody (1:500). The images shown are representative of at least 3 repetitions of the experiment. (TIF)

Figure S6 Incubation of HEK293 cells in medium with high levels of insulin does not diminish the cleavage of htt N171-18Q to cp-A/1. HEK293 cells were transfected with vectors for htt N171-18Q as described in Methods. 24 hours after transfection, insulin was added to the medium to a final concentration of 10 µg/ml and the cells were incubated a further 24 hours before harvest and immunoblot analysis with the antibody 2B4. For these experiments, cells were lysed by freeze thaw in PBS (2 cycles dry ice/ethanol bath and 42°C water bath) with insoluble material removed by centrifugation at 3000xg for 2 minutes. The image shown is representative of at least 3 independent repetitions of the experiment. (TIF)

Figure S7 Lack of accumulation of cp-A/1 like fragments in untransfected HEK293 cells. We compared untransfected HEK293 cells to cells transiently transfected with httN171-18Q for 48 h. Cells were treated with MG132 (lane 2 and 5) or chloroquine (lanes 3 and 6) to stabilize any htt fragments that may have been produced. We observe no obvious endogenous htt cleavage products in the HEK293 cells. (TIF)

Data File S1 Excel spreadsheets of raw data for expression profile of the HEK293 cells. See Methods for an explanation of how the data were analyzed. (XLS)

Data File S2 Excel spreadsheets of raw data for expression profile of the mouse L-TK- cells. See Methods for an explanation of how the data were analyzed. (XLS)

Acknowledgments
We thank Rick Morimoto, Ron Kopito, Erich Wanker and Gill Bates for discussions relating to the design of these analyses. We thank Thomas Ladd for advice on the use of DAPT and LY411,575.

Author Contributions
Performed the experiments: ATNT DRB. Contributed reagents/materials/analysis tools: TEG. Wrote the paper: ATNT DRB.

References
1. Huntington’s Disease Collaborative Research Group (1995) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72: 971-983.
2. de la Monte SM, Vonsattel JP, Richardson EP (1988) Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington’s disease. J Neuropathol Exp Neurol 47: 516–535.
3. Myers RH, Vonsattel JP, Cupples LA, Richardson EP, et al. (1988) Clinical and neuropathologic assessment of severity in Huntington’s disease. Neurology 38: 341–347.
4. Herndon ES, Hladik CL, Shang P, Burns DK, Raisanen J, et al. (2009) Neuronanatomic profile of polyglutamine immunoreactivity in Huntington’s disease brains. J Neuropathol Exp Neurol 68: 250–261.
5. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, et al. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brains. Science 277: 1960–1963.
6. Gutekunst CA, Li S, Yi H, Maloy JS, Krummelmeier S, et al. (1999) Nuclear and neuronal aggregates in Huntington’s disease: relationship to neuropathology. J Neurosci 19: 2532–2539.
7. Landes A, Lindenberg KS, Ben Haim R, Weber C, Devys D, et al. (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10: 259–269.
8. Schilling G, Kleveska A, Tebbenkamp AT, Juennemann K, Cooper J, et al. (2007) Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models. J Neuropathol Exp Neurol 66: 313–320.
9. Lendles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, et al. (2010) Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 285: 8080–8083.
10. Cooper JK, Schilling G, Peters MF, Herring WJ, Sharp AH, et al. (1998) Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 7: 783–790.
11. Martindale D, Hackam A, Wierzuck A, Ellerby L, Wellington C, et al. (1998) Length of huntingtin and its polyglutamine tract influences localization and differently build up cytoplasmic and nuclear inclusions. Mol Cell 10: 259–269.
12. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 495-506.
13. Schilling G, Becher MW, Sharp AH, Jinnah HA, Daan K, et al. (1999) Intranuclear inclusions and neuritic pathology in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8: 397–407.
14. Slov EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12: 1555–1567.
15. Gray M, Shirasaka DL, Cepeda C, Andre VM, Willburn B, et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28: 6103–6115.
16. Heng MY, Dedolph PJ, Albin RL (2008) Rodent genetic models of Huntington disease. Neurobiol Dis 32: 1–9.
17. Woodman B, Butler R, Lendles C, Lupton MK, Tse J, et al. (2007) The HD101/Q150/Q50 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res Bull 72: 83–97.
18. Kim YJ, Sapp E, Cullif BB, Golim L, Yoder J, et al. (2006) Lysosomal proteases are involved in generation of N-terminal huntingtin fragments. Neurobiol Dis 22: 346–356.
19. Ratovitski T, Nakamura M, D’Ambola J, Chigladze L, Liang Y, et al. (2007) N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington’s disease. Cell Cycle 6: 2970–2981.
20. Ratovitski T, Gueck M, Jiang H, Chigladze E, Walldun E, et al. (2009) Mutant Huntington N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem 284: 10855–10867.
21. Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, et al. (2000) Induced caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and non-neuronal cells. J Biol Chem 275: 19831–19838.
22. Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, et al. (2002) Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington’s disease. J Neurosci 22: 7862–7872.
23. Gafni J, Hermal E, Young JE, Wellington CL, Hayden MR, et al. (2004) Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 279: 20211–20220.
24. Miller JP, Holcomb J, Al Ranahi I, de Haro M, Gafni J, et al. (2010) Matrix metalloproteases are modifiers of huntingtin proteolysis and toxicity in Huntington’s disease. Neuroen 67: 199–212.
25. Fortun J, Verrier JD, Go JC, Madersky I, Dunn WA Jr, et al. (2007) The formation of peripheral myelin protein 22 aggregates is hindered by the enhancement of autophagy and expression of cytoplasmic chaperones. Neurobiol Dis 22: 252–265.
26. Sadasivan S, Waghray A, Larner SF, Dunn WA Jr, Hayes RL, et al. (2006) Aminic acid starvation induced autophagic cell death in PC-12 cells: evidence for activation of caspase-3 but not calpain-1. Apoptosis 11: 1573–1582.
27. Fauq AH, Simpson K, Maharvi GM, Golde T, Das P (2007) A multigram chemical synthesis of the gamma-secretase inhibitor LY411575 and its diastereoisomers. Bioorg Med Chem Lett 17: 6392–6395.

28. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227: 680–685.

29. Shaw G, Morse S, Ararat M, Graham FL (2002) Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J 16: 669–671.

30. Rawlings ND, Barrett AJ, Bateman A (2010) MEROPS: the peptidase database. Nucleic Acids Res 38: D227–D233.

31. Tompa P, Buzde-Lantos P, Tantos A, Farkas A, Szilagyi A, et al. (2004) On the sequential determinants of calpain cleavage. J Biol Chem 279: 20773–20785.

32. Saido TC, Nagao S, Shiramine M, Tsukaguchi M, Sorimachi H, et al. (1992) Autolytic transition of mu-calpain upon activation as resolved by antibodies distinguishing between the pre- and post-autolysis forms. J Biochem 111: 81–86.

33. Meyer SL, Buzdeko-Coyne D, Malila SK, Spain CM, Filkovsky R, et al. (1996) Biologically active monomeric and heterodimeric recombinant human calpain I produced using the baculovirus expression system. Biochem J 314 (Pt 2): 511–519.

34. Renna M, Jimenez-Sanchez M, Sarkar S, Rubinsztein DC (2010) Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases. J Biol Chem 285: 11061–11067.

35. Mizushima N (2004) Methods for monitoring autophagy. Int J Biochem Cell Biol 36: 2491–2502.

36. Youn YH, Cho KS, Hwang JJ, Lee SJ, Choi JA, et al. (2010) Induction of lysosomal dilatation, arrested autophagy, and cell death by chloroquine in cultured ARPE-19 cells. Invest Ophthalmol Vis Sci 51: 6030–6037.

37. Inagaki R, Tagawa K, Qi ML, Enokido Y, Ito H, et al. (2008) Omi/HtrA2 is relevant to the selective vulnerability of striatal neurons in Huntington's disease. Eur J Neurosci 28: 30–40.

38. Chatterjee S, Osnide M, Stauffer D, Morgan H, et al. (2006) Signal peptide peptidase dependent cleavage of type II transmembrane substrates releases intracellular and extracellular signals. Eur J Pharmacol 540: 10–17.

39. Kegel KR, Sapp E, Alexander J, Reeves P, Bleckmann D, et al. (2010) Huntington cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors. Mol Neurodegener 5: 58.

40. Lanz TA, Hooley JD, Adams WJ, Merchant KM (2004) Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[2S)-2-(3,5-difluorophenyl)-2-hydroxyethylamino]-N1-[7S)-5-methyl-6-oxo-6,7-dihydro-5H-thienzo[b,d]azein-7-yl]-L-alaninamide (LY-411575). J Pharmacol Exp Ther 309: 49–55.

41. Lanz TA, Fici GJ, Merchant KM (2005) Lack of specific amyloid-beta[1–42] suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J Pharmacol Exp Ther 312: 399–406.

42. De Strooper B, Safﬁg P, Craessaerts K, Vanderstichele H, Guhde G, et al. (1998) Deﬁciency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391: 367–370.